178 related articles for article (PubMed ID: 10905745)
1. Preclinical safety assessment: in vitro -- in vivo testing.
Højelse F
Pharmacol Toxicol; 2000; 86 Suppl 1():6-7. PubMed ID: 10905745
[TBL] [Abstract][Full Text] [Related]
2. Safety evaluation to support First-In-Man investigations II: toxicology studies.
Baldrick P
Regul Toxicol Pharmacol; 2008 Jul; 51(2):237-43. PubMed ID: 18501490
[TBL] [Abstract][Full Text] [Related]
3. The way forward in reproductive/developmental toxicity testing.
Spielmann H
Altern Lab Anim; 2009 Dec; 37(6):641-56. PubMed ID: 20105000
[TBL] [Abstract][Full Text] [Related]
4. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop.
Kirkland D; Pfuhler S; Tweats D; Aardema M; Corvi R; Darroudi F; Elhajouji A; Glatt H; Hastwell P; Hayashi M; Kasper P; Kirchner S; Lynch A; Marzin D; Maurici D; Meunier JR; Müller L; Nohynek G; Parry J; Parry E; Thybaud V; Tice R; van Benthem J; Vanparys P; White P
Mutat Res; 2007 Mar; 628(1):31-55. PubMed ID: 17293159
[TBL] [Abstract][Full Text] [Related]
5. Determination of genetic toxicity and potential carcinogenicity in vitro--challenges post the Seventh Amendment to the European Cosmetics Directive.
Tweats DJ; Scott AD; Westmoreland C; Carmichael PL
Mutagenesis; 2007 Jan; 22(1):5-13. PubMed ID: 17142828
[TBL] [Abstract][Full Text] [Related]
6. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs.
Jacobs A
Toxicol Lett; 2009 Apr; 186(1):32-5. PubMed ID: 18809476
[TBL] [Abstract][Full Text] [Related]
7. Proposed integrated decision-tree testing strategies for mutagenicity and carcinogenicity in relation to the EU REACH legislation.
Combes R; Grindon C; Cronin MT; Roberts DW; Garrod J
Altern Lab Anim; 2007 May; 35(2):267-87. PubMed ID: 17559315
[TBL] [Abstract][Full Text] [Related]
8. Preclinical safety of anecortave acetate.
Heaton J; Kastner P; Hackett R
Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S35-40. PubMed ID: 17240255
[TBL] [Abstract][Full Text] [Related]
9. Genetic toxicity assessment: employing the best science for human safety evaluation part III: the comet assay as an alternative to in vitro clastogenicity tests for early drug candidate selection.
Witte I; Plappert U; de Wall H; Hartmann A
Toxicol Sci; 2007 May; 97(1):21-6. PubMed ID: 17204584
[TBL] [Abstract][Full Text] [Related]
10. Integrated decision-tree testing strategies for mutagenicity and carcinogenicity with respect to the requirements of the EU REACH legislation.
Combes R; Grindon C; Cronin MT; Roberts DW; Garrod JF
Altern Lab Anim; 2008 Oct; 36 Suppl 1():43-63. PubMed ID: 19025331
[TBL] [Abstract][Full Text] [Related]
11. Preclinical safety profile of alendronate.
Peter C; Rodan GA
Int J Clin Pract Suppl; 1999 Apr; 101():3-8. PubMed ID: 12669734
[TBL] [Abstract][Full Text] [Related]
12. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
13. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
14. Notes to applicants for marketing authorizations on the pre-clinical biological safety testing of medicinal products derived from biotechnology (and comparable products derived from chemical synthesis). Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety of Medicines.
J Biol Stand; 1989 Jul; 17(3):203-12. PubMed ID: 2677013
[No Abstract] [Full Text] [Related]
15. The use of human cell line reporter gene-based assays in chemical toxicity testing.
Scrivens M; Bhogal N
Toxicol In Vitro; 2007 Oct; 21(7):1233-40. PubMed ID: 17604594
[TBL] [Abstract][Full Text] [Related]
16. Rodent carcinogenicity and toxicity, in vitro mutagenicity, and their physical chemical determinants.
Benigni R; Andreoli C
Mutat Res; 1993 Oct; 297(3):281-92. PubMed ID: 7692274
[TBL] [Abstract][Full Text] [Related]
17. How accurate is in vitro prediction of carcinogenicity?
Walmsley RM; Billinton N
Br J Pharmacol; 2011 Mar; 162(6):1250-8. PubMed ID: 21091657
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles.
Kirkland D; Aardema M; Müller L; Makoto H
Mutat Res; 2006 Sep; 608(1):29-42. PubMed ID: 16769241
[TBL] [Abstract][Full Text] [Related]
19. Safety assessment of biopharmaceuticals: Japanese perspective on ICH S6 guideline maintenance.
Nakazawa T; Kurokawa M; Kimura K; Wakata A; Hisada S; Inoue T; Sagami F; Heidel SM; Kawakami K; Shinoda K; Onodera H; Kumagai Y; Ohno Y; Kawamura N; Yamazaki T; Inoue T
J Toxicol Sci; 2008 Aug; 33(3):277-82. PubMed ID: 18670158
[TBL] [Abstract][Full Text] [Related]
20. First exposure in man: toxicological considerations.
Spindler P; Sjöberg P; Knudsen LE
Pharmacol Toxicol; 2000; 86 Suppl 1():8-12. PubMed ID: 10905746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
